<DOC>
	<DOCNO>NCT00238732</DOCNO>
	<brief_summary>The purpose study determine whether Bazedoxifine/conjugated estrogen effective treatment vaginal atrophy .</brief_summary>
	<brief_title>Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations Vasomotor Symptoms Associated With Menopause</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Generally healthy , postmenopausal woman , age 40 65 year Intact uterus At least 1 moderate severe vulvar/vaginal symptom bothersome Hypersensitivity estrogens , endometrial hyperplasia , know suspected estrogendependent neoplasia Thrombophlebitis , thrombosis thromboembolic disorder Neuroocular disease</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Vaginal Atrophy</keyword>
	<keyword>Postmenopause</keyword>
</DOC>